Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VOGX with free AI briefings, catalyst countdowns, and dilution alerts.

VOGX · Vogenx, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$82.1M Cash on Hand
179.3mo Cash Runway
Follow VOGX by email Get an email when VOGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VOGX, unsubscribe in one click. Privacy

📣 What VOGX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Mizagliflozin Postbariatric Hypoglycemia Phase 2 · NCT05721729 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VOGX holds $82.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.4M/quarter from operations, an estimated runway of 179.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 23 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VOGX files for a raise →

👥 Who Owns VOGX

Insiders 21.9% Institutions 24.5% Public and other holders 53.6%
HolderTypeShares% of sharesAs of
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 1,923,076 12.95% 2026-08-31
William Wilkison
Chief Scientific Officer, Director, 10% · +155,000 options
Insider 1,800,000 12.12% 2026-08-11
James Green
Chief Executive Officer, Director, 10% o · +155,000 options
Includes shares also reported by William Wilkison, counted once
Insider 1,800,000 12.12% 2026-08-11
Affinity Asset Advisors, LLC Institution (13G, 5%+) 915,000 6.16% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 800,000 5.39% 2026-09-30
Steven R Delmar
Chief Financial Officer, Director · +155,000 options
Insider 704,273 4.74% 2026-08-13
Richard Bentley Cheatham
10% owner
Insider 700,000 4.71% 2026-08-11
Peter Pieraccini
Director · +50,000 options
Insider 42,735 0.29% 2026-08-13

Share count 14,855,087 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VOGX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VOGX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.